Literature DB >> 20214208

Outcomes of total pelvic exenteration for colorectal cancer.

Minoru Nishio1, Chohei Sakakura, Tomoyuki Nagata, Atsushi Miyashita, Takuo Hamada, Hisashi Ikoma, Takeshi Kubota, Masayoshi Nakanishi, Akio Kimura, Daisuke Ichikawa, Syoujirou Kikuchi, Hitoshi Fujiwara, Kazuma Okamoto, Toshiya Ochiai, Yukihito Kokuba, Hiroki Taniguchi, Teruhisa Sonoyama, Akeo Hagiwara, Eigo Otsuji.   

Abstract

BACKGROUND/AIMS: Pelvic recurrence occurs in 4-33% of patients who have undergone a curative resection of primary rectal cancer and is thus a serious problem. However, the best treatment for primary rectal cancer remains unclear. In the present study was assessed the outcomes of total pelvic exenteration for colorectal cancer retrospectively.
METHODOLOGY: In the present study was investigated the medical charts of 25 patients who underwent total pelvic exenteration for primary colorectal cancer (n = 12) or postoperative local recurrence of colorectal cancer (n = 13) at the Department of Surgery (Division of Digestive Surgery) of the Kyoto Prefectural University of Medicine between the years 1997-2005.
RESULTS: The mean disease-free time interval between the first operation for primary colorectal cancer and total pelvic exenteration for the recurrence was 919 days (range, 203-3460 days). Total pelvic exenteration required a mean operation time of 940 minutes (range, 540-1395 minutes). The mean carcinoembryonic antigen (CEA) value was 25.5 ng/ml (range, 1-171.8 ng/ml). Five-year survival was achieved in 9 patients (36%) and inhospital death occurred in 3 patients (12%). The patients with curative resection survived significantly longer than the patients with non-curative resection.
CONCLUSIONS: When curative resection is achieved, total pelvic exenteration for colorectal cancer can result in long-term survival.

Entities:  

Mesh:

Year:  2009        PMID: 20214208

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  5 in total

Review 1.  Locally Advanced Disease and Pelvic Exenterations.

Authors:  Christos Kontovounisios; Paris Tekkis
Journal:  Clin Colon Rectal Surg       Date:  2017-12-01

Review 2.  Management of stage IV rectal cancer: palliative options.

Authors:  Sean M Ronnekleiv-Kelly; Gregory D Kennedy
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

3.  Outcomes of pelvic exenteration for recurrent or primary locally advanced colorectal cancer.

Authors:  Hwa Yeon Yang; Sung Chan Park; Jong Hee Hyun; Ho Kyung Seo; Jae Hwan Oh
Journal:  Ann Surg Treat Res       Date:  2015-08-24       Impact factor: 1.859

Review 4.  Palliative care and end-stage colorectal cancer management: the surgeon meets the oncologist.

Authors:  Renato Costi; Francesco Leonardi; Daniele Zanoni; Vincenzo Violi; Luigi Roncoroni
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

5.  Efficacy of an additional flap operation in bladder-preserving surgery with radical prostatectomy and cystourethral anastomosis for rectal cancer involving the prostate.

Authors:  Keita Noguchi; Yuji Nishizawa; Yoshinobu Komai; Yasuyuki Sakai; Akihiro Kobayasi; Masaaki Ito; Norio Saito
Journal:  Surg Today       Date:  2017-03-04       Impact factor: 2.549

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.